Together, our findings suggest that foretinib attenuates postmenopausal osteoporosis by suppressing cellular senescence through the p53–p21/p16–Rb pathway axes, decreasing SASP secretion, and restoring osteogenic capacity (Figure 4B). Here, TP53 is linked to postmenopausal osteoporosis.